Galapagos (GLPG.AS) Osake Kurssi
Galapagos Kurssi
Liikevaihto on kasvanut 19,9 % vuodessa viimeisten 19 vuoden aikana 1,11 Mrd. EUR:een. Osakekohtainen tulos on kasvanut 25,0 % vuodessa viimeisten 16 vuoden aikana. Galapagosn nettomarginaali on nyt 28,9 %, noussut −25,9 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 28,46 EUR, eli yli nykyhintaa 6,8 %. 18 analyytikosta 3 suosittaa ostoa — kokonaiskonsensus on Myy.
Galapagos osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Galapagos liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Galapagos -osakkeesta
The business model of Galapagos NV is centered around the discovery, development, and commercialization of innovative medicines. The company primarily focuses on the development of small molecule drugs that target specific proteins involved in various diseases. With a strong emphasis on research and development, Galapagos NV collaborates with partners in the pharmaceutical industry to bring novel therapies to patients. By leveraging its proprietary target discovery platform, the company identifies potential drug targets and advances them through preclinical and clinical development stages. Through strategic collaborations and licensing agreements, Galapagos NV aims to bring its pipeline of promising drug candidates to market, addressing unmet medical needs and contributing to improved patient outcomes.
Galapagos NV is primarily active in the biotechnology and pharmaceutical industries.
Galapagos NV faces competition from various pharmaceutical companies in the market. Some of the main competitors include companies like Novartis, Johnson & Johnson, Pfizer, and Roche. These companies operate in similar therapeutic areas and compete with Galapagos NV in developing innovative drug candidates and therapies. Galapagos NV strives to maintain a competitive edge by leveraging its distinctive scientific expertise, robust pipeline, and strategic collaborations.
Galapagos NV is a renowned biotechnology company headquartered in Mechelen, Belgium. Founded in 1999, Galapagos NV has established itself as a leader in drug discovery and development. The company focuses on the discovery and development of small molecule medicines with a specialization in inflammation, fibrosis, and other diseases. Galapagos NV has an excellent track record of successful collaborations with pharmaceutical giants such as Gilead Sciences. With a strong commitment to innovation and advancement, Galapagos NV continues to make significant contributions to the healthcare industry, bringing hope and potential for novel treatments to patients worldwide.
Galapagos NV, a renowned biotechnology company, has accomplished several notable milestones over the years. The company has made significant progress in developing innovative therapies for various diseases. It successfully advanced its lead drug candidate, Filgotinib, through multiple clinical trials, demonstrating promising results in treating rheumatoid arthritis, Crohn's disease, and other inflammatory conditions. Galapagos NV has also fostered strong partnerships with major pharmaceutical companies to further advance its research pipeline. Furthermore, the company received regulatory approvals for its products in various regions, solidifying its position as a pioneer in the biotech industry. Galapagos NV continues to drive innovation, striving to improve patients' lives through groundbreaking discoveries.
Galapagos NV primarily operates in several countries and regions. The company has a significant presence in Europe, specifically in Belgium and the Netherlands, where its headquarters are located. Galapagos also has operations and offices in France, Spain, Italy, Switzerland, and the United Kingdom. Furthermore, the company has expanded its footprint across the Atlantic, with a presence in the United States and Canada. With its global presence, Galapagos NV is able to leverage diverse markets and collaborations to further its research, development, and commercialization efforts.
Galapagos NV represents a commitment to innovation, collaboration, and scientific excellence. The company values diversity and fosters an entrepreneurial spirit within its teams. Galapagos NV's corporate philosophy revolves around a patient-centric approach, aiming to develop transformative medicines that improve the lives of patients. By leveraging cutting-edge technology and extensive research, the company strives to bring forth breakthrough therapies for various diseases. Galapagos NV's dedication to research and development, along with its emphasis on partnerships and scientific expertise, drives its mission to deliver innovative solutions to healthcare challenges.
Analyytikot asettavat tällä hetkellä Galapagos-osakkeelle keskimääräisen tavoitehinnan 30,17 EUR (mediaani: 28,46 EUR), mikä merkitsee +13,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 18 analyytikkoarvioon.
18 analyytikkoa arvioi tällä hetkellä Galapagos-osaketta: 3 suosittaa ostoa, 6 pitoa ja 9 myyntiä. Vuodelle 2026 analyytikot odottavat Galapagos-yhtiöltä 271,90 M EUR liikevaihtoa ja −3,05 EUR osakekohtaista tulosta.
Galapagos-osake (GLPG.AS) on listattuna 10 pörssissä, muun muassa: London (0JXZ.L), XETRA (GXE.DE), Frankfurt (GXE.F), München (GXE.MU), Düsseldorf (GXE.DU), Wien (GLPG.VI), Amsterdam (GLPG.AS).
Galapagos NV is a biotechnology company specialized in the discovery and development of new drugs for a variety of diseases. Its business model is based on a three-step strategy: Target Discovery, Drug Development, and Clinical Candidate Development. The company uses proprietary technologies, including AI methods and big data analysis, to identify promising target molecules and develop potential drugs. These drugs are then tested for efficacy and safety in clinical studies, with the goal of bringing new treatments to market faster and more efficiently. Galapagos also collaborates with other companies and organizations to develop innovative treatment options, such as their partnership with Gilead Sciences for the development of drugs for Idiopathic Pulmonary Fibrosis. Overall, Galapagos strives to advance the discovery and development of drugs for various diseases through the use of innovative technologies and collaboration with experts in the field.
odotettu liikevaihto Galapagos on 271,90 M EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Galapagos on −200,96 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Galapagos:n hinta-voitto-suhde (P/E) on tällä hetkellä −8,73. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Galapagos-osakkeen arvostusta.
Galapagos:n hinta-myynti-suhde (P/S) on tällä hetkellä 6,46. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Galapagos-osakkeen arvostuskennuslukuna.
Galapagos:n Eulpool-laatuscore on 5/10.
Galapagos:n ISIN on BE0003818359. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Galapagos:n WKN on A0EAT9. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Galapagos:n ticker on GLPG.AS. Tämä pörssinoteeraus käytetään Galapagos-osakkeiden kauppaan pörssissä.
Galapagos osake
Kaikki tunnusluvut ja syvällinen analyysi Galapagos:sta
Meidän osakeanalyysimme Galapagos-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Galapagos:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: